Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Epigenetic drivers of disease progression in multiple myeloma

Felipe Prosper • 28 Sep 2023
IMS 2023
Multiple Myeloma Rare Diseases Smoldering Myeloma

In this video, Felipe Prosper, MD, PhD, University of Navarra, Pamplona, Spain, discusses the role of epigenetics in the pathogenesis of multiple myeloma, highlighting novel transcription factors that have been identified and may play a role in disease progression, including IRF-2. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Felipe Prosper

1:44
The impact of CAR density on the antitumoral efficacy of BCMA CAR-T cells in multiple myeloma
Felipe Prosper • 28 Sep 2023
1:00
The role of the immune microenvironment in disease progression in multiple myeloma
Felipe Prosper • 28 Sep 2023

Related Videos

1:36
Identification of high-risk disease using Molecular profiling by Mymap
Gareth Morgan • 26 Feb 2016
2:33
Where do new drugs fit into the treatment landscape of multiple myeloma?
Joseph Mikhael • 5 Feb 2016
1:29
Treatment outcomes of elderly patients with AL Amyloidosis
Giampaolo Merlini • 4 May 2018
10:26
Myeloma 2016: Panel discussion on the application of genomics studies
Leif Bergsagel et al. • 14 Jun 2016
The content of VJHemOnc is intended for healthcare professionals